Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer

摘要: BACKGROUND. Epidermal growth factor receptor (EGFR, HER-1, and erbB1) is overexpressed in primary breast cancer had been identified as a poor prognostic factor. METHODS. Pretreatment serum EGFR levels were quantified by using an enzyme-linked immunoadsorbent assay Phase III first-line trial of letrozole tamoxifen correlated with patient outcomes. RESULTS. Serum control group 117 healthy, postmenopausal women measured 64.1 ± 13.3 ng/mL (mean standard deviation). Using cutoff level 44.1 from the (5% nonparametric method), 53 535 patients (10%) decreased EGFR. Patients no significant difference objective response rate (ORR), clinical benefit (CBR), time to progression (TTP), or treatment failure (TTF); however, they did have significantly reduced survival compared who normal (median survival, 23.3 months vs. 30.9 months; P = .007). A combined analysis pretreatment HER-2 yielded additional predictive information for ORR, CBR, TTP, TTF alone. However, current analysis, subgroup was (n 39 patients; 7.3%) that both 23.5 37.1 .005). In multivariate remained independent (hazards ratio, 1.58; .007). CONCLUSIONS. In metastatic cancer, EGFR/normal predicted shorter EGFR/HER-2. This deserves further study assess their selection anti-EGFR-directed therapies. Cancer 2006. © 2006 American Society.